Access Solutions

Reimbursement Support

To speak live with one of our Specialists, call (866) 681-3261 from 6 a.m.–5 p.m. PT, Monday to Friday, fax (866) 681-3288 or visit RituxanAccessSolutions.com

Resources for healthcare professionals Print Page

The following resources are available for you to download and keep.

Download:

Attention Healthcare Provider: Provide Medication Guide to patient prior to Rituxan infusion.
Download the Rituxan Medication Guide
[ Rituxan_MedicationGuide.pdf | 432KB ]

A comprehensive pocket brochure on RITUXAN
Download pocket brochure on RITUXAN
[ RA_PocketBrochure.pdf | 1.1MB ]

A tear pad for healthcare providers
Download the Healthcare Provider Checklist
[ RA_Tear_Pad_HCP_Checklist.pdf | 180KB ]

The video Roles of B Cells in RA and the MOA of RITUXAN
Download the Quicktime video: Roles of B Cells in RA and the MOA of RITUXAN
[ rituxanVid_moa_dl.mp4 | 36.1 MB ]
Download the Windows Media Player video: Roles of B Cells in RA and the MOA of RITUXAN
[ rituxanVid_moa_dl.wmv | 31.8 MB ]
View the video on the MOA page


Reprint requests

Call 1-877-474-8892 (then press 3 / 2 / 2) to request the following documents:

Next Section: Useful Links

 

Indication

Rituxan® (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

Important Safety Information

  • Rituxan has been associated with fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy (PML)
  • Hepatitis B reactivation, cardiac arrhythmias, and angina have also been observed
  • Patients should be closely observed for signs of infection if biologic agents and/or DMARDs other than methotrexate are used concomitantly
  • Common adverse reactions include infusion reactions and infections

Please see full prescribing information, including Boxed Warnings for additional safety information.